Recent clinical success of antibody-drug conjugates is resparking interest in the technology for tackling unmet cancer needs. Sarah Webb investigates.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Webb, S. Back on target. Nat Biotechnol 31, 191–193 (2013). https://doi.org/10.1038/nbt.2520
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2520
This article is cited by
-
Site-specific chemical modification of antibody fragments using traceless cleavable linkers
Nature Protocols (2013)